Valuation: Neuronetics, Inc.

Market Cap 222M 194M 182M 166M 312M 21.2B 312M 2.19B 843M 10.82B 833M 814M 34.9B P/E 2026 *
-8.37x
P/E 2027 * -10.4x
Enterprise Value 222M 194M 182M 166M 312M 21.2B 312M 2.19B 843M 10.82B 833M 814M 34.9B EV / Sales 2026 *
1.37x
EV / Sales 2027 * 1.25x
Free-Float
69.12%
Yield 2026 *
-
Yield 2027 * -
1 day+2.11%
1 week+3.93%
Current month+2.46%
1 month-3.00%
3 months+142.50%
6 months+100.69%
Current year+110.87%
1 week 2.73
Extreme 2.73
3.04
1 month 2.63
Extreme 2.63
3.25
Current year 0.8
Extreme 0.8
3.44
1 year 0.8
Extreme 0.8
3.44
3 years 0.52
Extreme 0.52
5.92
5 years 0.52
Extreme 0.52
6.95
10 years 0.52
Extreme 0.52
39.39
Manager TitleAgeSince
Chief Executive Officer 63 2026-03-22
Director of Finance/CFO 51 2026-07-22
Chief Operating Officer 69 2025-06-18
Director TitleAgeSince
Director/Board Member 67 2017-06-30
Director/Board Member 65 2019-09-30
Chairman 71 2021-05-26
Date Insider Type Main position Quantity % Market Cap. Importance
8/14/26 Buy 14,000 0.0212%
7/23/26 Free

Chief Financial Officer

500,000 0.7561%
7/14/26 Buy 35,000 0.0529%
Change 5-day change 1-year change 3-year change Capi.($)
+2.11%+3.93%+2.46%+122.14% 217M
-0.04%+2.67%+38.64%+30.97% 244B
+2.43%+5.60%+16.08%-10.98% 152B
+0.11%+6.61%-9.55%+39.52% 142B
+2.74%+2.39%-53.71%-16.19% 63.36B
+0.50%+3.55%+20.38%+27.45% 50.92B
-1.42%-3.70%-20.21%-21.15% 48.47B
+3.29%+11.31%+32.40%+50.13% 45.66B
+0.43%+2.07%+40.75%+58.27% 41.65B
+3.62%+11.32%+143.83%+86.85% 36.06B
Average +1.38%+4.78%+21.11%+36.70% 82.35B
Weighted average by Cap. +0.98%+4.41%+18.84%+22.71%

Financials

2026 *2027 *
Net sales 162M 142M 133M 121M 228M 15.49B 228M 1.6B 616M 7.91B 608M 595M 25.5B 177M 155M 145M 133M 249M 16.92B 249M 1.74B 673M 8.64B 665M 650M 27.86B
Net income -25.45M -22.24M -20.9M -19.08M -35.8M -2.43B -35.81M -251M -96.81M -1.24B -95.57M -93.48M -4.01B -21.7M -18.96M -17.82M -16.26M -30.53M -2.07B -30.53M -214M -82.54M -1.06B -81.49M -79.71M -3.42B
Net Debt - -
Logo Neuronetics, Inc.
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Employees
658
Date Price Change Volume
26-09-22 US$2.910 +2.11% 809,537
26-09-21 US$2.850 -1.72% 627,958
26-09-18 US$2.900 -2.36% 1,120,477
26-09-17 US$2.970 +7.61% 1,043,690
26-09-16 US$2.760 -1.43% 1,549,697
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.910USD
Average target price
5.750USD
Spread / Average Target
+97.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STIM Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!